Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026
Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026
Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Fineline Cube Aug 31, 2026
Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Fineline Cube Aug 31, 2026
Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026
Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Fineline Cube Sep 1, 2026
Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Fineline Cube Sep 1, 2026
Company R&D

Burning Rock Biotech Launches PREVENT Study for Early Cancer Detection

Fineline Cube Jul 1, 2022

Chengdu-based medical device firm Burning Rock Biotech Ltd (NASDAQ: BNR) announced the launch of a...

Company Deals

Harbour BioMed’s Partner NK Celltech Raises RMB 100M in Series A Financing

Fineline Cube Jul 1, 2022

China-based Harbour BioMed (HKG: 2142) announced that its strategic partner NK Celltech, a company focusing...

Policy / Regulatory

NMPA Releases 55th Batch of Reference Drugs for Generic Evaluation

Fineline Cube Jul 1, 2022

The National Medical Products Administration (NMPA) has released the 55th batch of reference drugs for...

Company Drug

BeiGene’s Tislelizumab Shows Survival Benefit in Esophageal Cancer Study

Fineline Cube Jul 1, 2022

BeiGene (NASDAQ: BGNE) has released the latest results of the global Phase III RATIONALE 306...

Policy / Regulatory

NMPA Releases Work Plans for Temporary Import of Urgently Needed Drugs

Fineline Cube Jul 1, 2022

The National Medical Products Administration (NMPA) has officially released the “Work Plan for the Temporary...

Company Drug

Huadong Medicine’s Biosimilar Ozempic (Semaglutide) Wins NMPA Clinical Trial Approval

Fineline Cube Jul 1, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that a clinical trial filing for its...

Drug

Jixing Pharmaceuticals Enrolls First Patient in Etripamil Phase III Study for PSVT

Fineline Cube Jul 1, 2022

China-based Ji Xing Pharmaceuticals Ltd (Jixing) announced the first patient enrollment in a Phase III...

Company Drug

Takeda’s Obizur Prioritized for Review in Acquired Hemophilia A Treatment

Fineline Cube Jul 1, 2022

The Center for Drug Evaluation (CDE) website indicates that Takeda Pharmaceutical Co., Ltd’s Obizur (susoctocog...

Company Deals

Corestar Biotech Secures Series A Funding for POCT R&D Expansion

Fineline Cube Jun 30, 2022

Shenzhen-based point-of-care testing (POCT) specialist Corestar Biotechnology Co., Ltd has raised “tens of millions” of...

Company Deals

Great Robotics Raises RMB 100M for Surgical Robot Development

Fineline Cube Jun 30, 2022

Great Robotics, a Beijing-based medical robotics company, has reportedly raised close to RMB 100 million...

Company Deals

Visum Pharma Series B+ Financing to Advance R&D and GMP Workshop Construction

Fineline Cube Jun 30, 2022

Visum Pharmaceutical Co., Ltd reportedly raised close to RMB 100 million (USD 14.9 million) in...

Company Deals

Yunnan Jianzhijia Plans Acquisition of Hebei Tangren Pharmacy in USD 309 Million Deal

Fineline Cube Jun 30, 2022

China-based Yunnan Jianzhijia Health-Chain Co, Ltd (SHA: 605266) plans to acquire 100% of compatriot firm...

Policy / Regulatory

Sun Pharma Loses VBP Bid for Bicalutamide in China Due to Quality Failures

Fineline Cube Jun 30, 2022

The Shanghai Medical Products Administration (SMPA) has revoked the winning bid of India-based Sun Pharmaceutical...

Company Drug

Allist Pharmaceuticals’ Furmonertinib Receives NMPA Approval for First-Line NSCLC Treatment

Fineline Cube Jun 30, 2022

Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) announced that it has received another indication approval from...

Company Deals

Dakang Medical Secures RMB 400M in Series E Round for Hemodialysis Center Expansion

Fineline Cube Jun 30, 2022

Dakang Medical (DiaCare Medical), a Beijing-based provider of blood purification chain medical services, has reportedly...

Company Drug

Ascentage Pharma’s APG-5918 Receives FDA Approval for First-in-Human Study

Fineline Cube Jun 30, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) announced that it has received approval from the US Food...

Company Deals

Luzhu Bio Files for Hong Kong IPO After RMB 4.42 Billion Valuation

Fineline Cube Jun 30, 2022

Beijing Luzhu Biotechnology Co., Ltd, a leading developer of human vaccines and therapeutic biologics, has...

Company Deals

Youwe Bio’s Series B Financing to Advance Microneedle Technology Commercialization

Fineline Cube Jun 30, 2022

China-based Youwe (Zhuhai) Biotechnology Co., Ltd, a developer of soluble microneedle transdermal drug delivery technology,...

Policy / Regulatory

NHSA Updates NRDL with Focus on Expert Review and Simplified Renewals

Fineline Cube Jun 30, 2022

The National Healthcare Security Administration (NHSA) has released the “2022 National Reimbursement Drug List (NRDL)...

Company Drug

Ascletis Pharma Doses First Patient in China’s Phase II Trial for HIV-1 Treatment with ASC22

Fineline Cube Jun 29, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced the dosing of the first patient in its...

Posts pagination

1 … 704 705 706 … 714

Recent updates

  • NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment
  • Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment
  • Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States
  • Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market
  • Laekna Doses First Patient in Phase I Study of LAE118 PI3Kα Inhibitor for Advanced Solid Tumors, Licensed to Vasque Bio for Up to USD 527 Million
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Company Drug

Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States

Policy / Regulatory

Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.